ENTYVIO is a biologic treatment for moderate to severe Crohn's disease (CD) or ulcerative colitis (UC). See Safety and Prescribing Information.

Learn more about ENTYVIO® (vedolizumab), a biologic treatment for moderate to severe ulcerative colitis or Crohn's disease in adults.

The incidence of anti-drug antibodies to ENTYVIO using a drug-tolerant ECL method for patients in SC UC Trial who had continuous treatment for 52 weeks was 6% (6 out of 106 total patients …

Infusion-related and serious allergic reactions. These reactions can happen while you are receiving ENTYVIO or several hours after treatment. You may need treatment if you have an …

THE ENTYVIO PEN The ENTYVIO Pen is approved for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) after at least 2 intravenous (IV) …

Apr 15, 2025 · Takeda Pharmaceutical's ENTYVIO (vedolizumab) Overview Vedolizumab is a biologic medication approved for both intravenous (IV) and subcutaneous (SC) use, with …

Oct 27, 2025 · For those battling ulcerative colitis, entyvio vedolizumab treatment for ulcerative colitis patients offers targeted relief by focusing on gut inflammation without broadly …

Apr 15, 2025 · Building on these results, Entyvio —the branded formulation of vedolizumab—has emerged as a leading treatment for IBD. By leveraging a gut-selective mechanism, Entyvio …

4 days ago · The request for continuation of vedolizumab (Entyvio) maintenance therapy for 9 months is NOT medically necessary in this case because the patient is being switched to …

The only gut-focused treatment* for Crohn’s and UC that works right where need it *ENTYVIO helps block certain inflammation-causing cells from entering the gut. Ask your healthcare …